CAMBRIDGE, Mass., May 17, 2023 Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that. | May 17, 2023
Prime Medicine, Inc. (NYSEARCA:PRME – Get Rating) major shareholder 2019 Gp L.L.C. Gv sold 27,290 shares of the company’s stock in a transaction that occurred on Friday, May 12th. The stock was sold at an average price of $12.72, for a total transaction of $347,128.80. Following the completion of the sale, the insider now directly […]
Prime Medicine, Inc. (NYSEARCA:PRME – Get Rating) major shareholder 2019 Gp L.L.C. Gv sold 157,952 shares of the firm’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $12.74, for a total transaction of $2,012,308.48. Following the sale, the insider now directly owns 10,800,973 shares in the […]
Prime Medicine, Inc. (NYSEARCA:PRME – Get Rating) major shareholder 2019 Gp L.L.C. Gv sold 100,772 shares of the firm’s stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $14.13, for a total transaction of $1,423,908.36. Following the sale, the insider now owns 11,421,476 shares of […]
Shares of Prime Medicine, Inc. (NYSEARCA:PRME – Get Rating) were down 4.6% during mid-day trading on Friday . The stock traded as low as $14.26 and last traded at $14.43. Approximately 41,304 shares were traded during trading, a decline of 77% from the average daily volume of 181,909 shares. The stock had previously closed at […]